In intramuscular (i / m) administration the maximum concentration achieved within 10 min after injection. The distribution of ondansetron are equally intramuscular and intravenous administration. The volume of distribution (Vd) when the equilibrium state is 140 liters, binding to plasma proteins – 70-76%. From the systemic circulation ondansetron is eliminated mainly by metabolism in the liver, with the participation of several enzyme systems. With the urine in unchanged form stands out less than 5% of the drug.
Lack isoenzyme trenbolone hexahydrobenzylcarbonate(debrizohina polymorphism) has no effect on the pharmacokinetics of ondansetron. The for parenteral administration, as well as after oral administration is about 3 hours. The pharmacokinetic parameters of ondansetron do not change during its repeated use. Pharmacokinetics in specific clinical situations. In patients with a creatinine clearance of 15-60 ml / min a reduced systemic clearance and Vd ondansetron, resulting in a small and clinically insignificant increase . The pharmacokinetics of ondansetron virtually unchanged in patients with severe renal impairment on hemodialysis. In patients with severe hepatic impairment is sharply reduced systemic clearance of ondansetron, as a result, it increases . In the application of ondansetron children observed decrease in clearance and the absolute , while the amount of change depends on the age.
– Prevention and relief of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy.
– Prevention and relief of nausea and vomiting in postoperative period.
Hypersensitivity to ondansetron, other selective serotonin 5HT 3 receptor antagonists and other ingredients; Pregnancy and breast-feeding; Children under 2 years old (insufficient efficacy and safety data).
In violation of cardiac rhythm and conduction, the simultaneous use of antiarrhythmic agents or beta-blockers, electrolyte imbalance, liver failure, intestinal obstruction (including suspicion).
Dosing and Administration
. Cytostatic therapy The choice of dosage trenbolone hexahydrobenzylcarbonate regimen is determined by the severity of the action carried out by emetogenic anticancer therapy. For adults, the daily dose usually is 8-32 mg, recommended the following modes: a moderate emetogenic chemotherapy or radiotherapy: 8 mg intravenous (i / v) or slow bolus / m immediately before beginning therapy, in vysokoemetogennoy chemotherapy: – 8 mg / jet slowly immediately before chemotherapy, followed by another two in / jet injections of 8 mg each of which is carried out with intervals of 2-4 hours; – continuous 24-hour / in infusion at a dose of 24 mg at 1 mg / hour; – 16-32 mg diluted in 50-100 ml of the appropriate infusion solution in the form of a 15-min / infusion, immediately before the start of chemotherapy . The effectiveness of ondansetron may be increased by a single on / in a glucocorticoid (e.g., 20 mg dexamethasone) before chemotherapy. encouraged to continue the use of the drug inside to prevent delayed emesis occurring at 24 hours after initiation of chemotherapy or radiotherapy, 8 mg 2 times . daily for 5 days in children over 2 years administered in a dose of 5 mg / m² body surface / w immediately before chemotherapy, followed by ingestion of a dose of 4 mg every 12 hours; after chemotherapy is recommended to continue the treatment with 4 mg twice a day orally for 5 days.
The prevention of postoperative nausea and vomitingadult is administered a single dose of 4 mg / m or / jet slowly at the start of anesthesia. For relief occurred nausea and vomiting recommended / m or slow in / in a 4 mg. / m in the same ondansetron area of the body can be introduced at a dose that does not exceed 4 mg! Children over 2 years for the prevention of postoperative nausea and vomiting ondansetron used exclusively parenterally in a single dose of 0.1 mg / kg (up to 4 mg) as a slow I / injection immediately before, during or after anesthesia. advisable slow / in a single treatment for which developed post-operative nausea and vomiting in children dose of 0.1 mg / kg (up to 4 mg). Older patients and patients with renal impairment change dosing regimen is not required. in liver injury is greatly reduced clearance ondansetron, and it increases trenbolone exahydrobenzylcarbonate from plasma and should not be .